For research and educational purposes only. Not medical advice.
GHRP-6 Reference
Educational, not medical advice reference for GHRP-6: GH Release; regulatory status, evidence posture, source review, and schedule notes. Also known as SKF-1…
Reference summary
Early human GH-response work in healthy volunteers documented GH secretion following GHRP-6 administration. Evidence is older and primarily short-term; long-term clinical outcome data are limited, and no modern PK/PD or outcome program comparable to ipamorelin or CJC-1295 exists.
- Categories
- GH Release
- Aliases
- SKF-110679, Growth hormone releasing hexapeptide
- Evidence posture
- translational — Evidence is limited to older, short-term human GH-response studies without modern PK/PD or outcome follow-up. Strong ghrelin-class appetite stimulation is consistently reported.
- Regulatory status
- No FDA-approved GHRP-6 drug label. FDA lists GHRP-6 among bulk drug substances with safety-risk concerns for compounding.
- Content review status
- research reference